Optimized Anti-tl1a antibodies

An antibody and antigen technology, applied in the direction of antibodies, antibody medical components, anti-inflammatory agents, etc., can solve the problems of IBD patients without targeted therapy, and achieve the effects of reduced therapeutic effect, high binding affinity, increased degradation and reduced degradation

Pending Publication Date: 2021-03-30
PROMETHEUS BIOSCI INC
View PDF44 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few targeted therapies for IBD patients, especially those who may not respond to existing IBD therapies (eg, anti-TNFα inhibitors)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Optimized Anti-tl1a antibodies
  • Optimized Anti-tl1a antibodies
  • Optimized Anti-tl1a antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0167] Example 1: Generation and Characterization of Humanized Anti-TL1A Antibodies

[0168] Humanize murine anti-TL1A antibody to reduce potential immunogenicity. A first variant, 12835, was generated consisting of murine 5C3D11 CDRs (SEQ ID NO:9, 12, 15, 18, 21, 24) grafted into a human variable region framework to generate a CDR comprising SEQ ID NO:26 A heavy chain variable region and a light chain variable region comprising SEQ ID NO:28. Unfortunately, clone 12835 contained nine (9) framework backmutations (murine framework residues), resulting in an incompletely humanized variant. Full humanization is essential to reduce the chance of a subject developing an immune response to the administered antibody. Therefore, the goal was to generate humanized antibodies comprising fewer murine framework residues while retaining the functional activity of the parental 12835 antibody. Unfortunately, murine framework residues that are critical to antibody function cannot be directl...

Embodiment 2

[0201] Example 2: Generation and Characterization of Anti-TL1A Antibodies with Optimized CDRs

[0202] In order to identify CDR mutations that could restore and improve the binding activity of the CDR-grafted construct (completely human germline framework), all of Mutagenesis was performed at each position of the six CDRs (LCDR1, LCDR2, LCDR3, HCDR1, HCDR2 and HCDR3). Initially, one library was synthesized at each position of HCDR3 and LCDR3. These positional libraries were screened by capture boosting with a theoretical diversity of 32 codons / 20 amino acids / 1 stop codon. In some cases, each position was screened by itself (theoretical diversity of the library equals 32), while in other cases the positions for specific CDRs were pooled and screened as a CDR library (theoretical diversity of the library equals 32 times the number of positions combined; for example, HCDR3 consists of 7 positions, so a theoretical library size of 32 x 7 equals 224 members). Libraries were scre...

Embodiment 3

[0229] Example 3. Generation and characterization of anti-TL1A antibodies with optimized CDRs using a mutated (S93) heavy chain

[0230] Clones containing CDR-grafted heavy chains (CDR-grafted and 21-3) had lower binding activity than clones containing a murine backmutation (S) at position 93 of the heavy chain. Therefore, another HCDR3 library was constructed. Libraries were constructed as described above, except that degenerate oligonucleotides from all positions were pooled prior to mutagenesis, and the library was synthesized and expressed as a pool, as opposed to examining each position individually. Similar to the HCDR3 position scan performed on the L8 heavy chain backbone (S93A), multiple mutations at position 102 of HCDR3 resulted in enhanced antigen binding in the capture-promoted form. Screening of the HCDR3 library based on the heavy chain S93 template identified some mutations identified on the heavy chain A93 template, but also identified novel mutations not pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 662,605, filed April 25, 2018, and U.S. Provisional Application No. 62 / 756,494, filed November 6, 2018, which are incorporated herein by reference. Background technique [0003] Inflammatory bowel disease (IBD) is a collective term for intestinal disorders that cause an inflammatory condition of the gastrointestinal tract. The main types of IBD are ulcerative colitis (UC) and Crohn's disease (CD). These diseases are so common that approximately 1.86 million people worldwide are diagnosed with UC and approximately 1.3 million people worldwide are diagnosed with CD. [0004] Each of these forms has various subclinical phenotypes that are characteristic of severe forms of IBD present in subsets of CD and UC patients. One such condition is obstructive Crohn's disease, which can be caused by long-term inflammation that can lead to scarring (fibrous ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/18
CPCC07K16/2875C07K2317/565C07K2317/55C07K2317/24C07K2317/76C07K2317/92C07K2317/52C07K2317/524C07K2317/71A61P29/00A61P37/06A61P1/04A61K2039/505A61K39/3955C07K16/24C07K16/241C07K16/28C07K2317/56C07K2317/732C07K2317/734C07K2317/90A61P1/00A61K9/0019C12N15/09C12N15/63C12N5/10
Inventor 杰弗里·D·沃特金斯辛迪·T·迪克森J·蒙迪·沃特金斯帕特丽夏·麦克内利
Owner PROMETHEUS BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap